Kestra Private Wealth Services’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $436K | Buy |
2,872
+943
| +49% | +$143K | 0.01% | 1098 |
|
|
2025
Q1 | $290K | Sell |
1,929
-115
| -6% | -$17.3K | ﹤0.01% | 1218 |
|
|
2024
Q4 | $377K | Buy |
2,044
+136
| +7% | +$25.1K | 0.01% | 1044 |
|
|
2024
Q3 | $376K | Buy |
1,908
+19
| +1% | +$3.74K | 0.01% | 999 |
|
|
2024
Q2 | $390K | Sell |
1,889
-16
| -0.8% | -$3.31K | 0.01% | 931 |
|
|
2024
Q1 | $516K | Buy |
1,905
+10
| +0.5% | +$2.71K | 0.01% | 784 |
|
|
2023
Q4 | $448K | Buy |
1,895
+95
| +5% | +$22.5K | 0.01% | 773 |
|
|
2023
Q3 | $353K | Buy |
1,800
+236
| +15% | +$46.3K | 0.01% | 794 |
|
|
2023
Q2 | $329K | Sell |
1,564
-31
| -2% | -$6.52K | 0.01% | 788 |
|
|
2023
Q1 | $322K | Buy |
1,595
+78
| +5% | +$15.7K | 0.01% | 760 |
|
|
2022
Q4 | $331K | Buy |
+1,517
| New | +$331K | 0.02% | 644 |
|
|
2022
Q3 | – | Sell |
-2,179
| Closed | -$466K | – | 920 |
|
|
2022
Q2 | $466K | Sell |
2,179
-16
| -0.7% | -$3.42K | 0.03% | 528 |
|
|
2022
Q1 | $623K | Sell |
2,195
-2,566
| -54% | -$728K | 0.03% | 505 |
|
|
2021
Q4 | $1.79M | Buy |
4,761
+52
| +1% | +$19.6K | 0.09% | 248 |
|
|
2021
Q3 | $1.94M | Sell |
4,709
-80
| -2% | -$33K | 0.11% | 205 |
|
|
2021
Q2 | $1.77M | Sell |
4,789
-62
| -1% | -$22.9K | 0.11% | 214 |
|
|
2021
Q1 | $1.41M | Sell |
4,851
-1,618
| -25% | -$469K | 0.1% | 228 |
|
|
2020
Q4 | $1.61M | Sell |
6,469
-100
| -2% | -$24.9K | 0.12% | 192 |
|
|
2020
Q3 | $1.49M | Buy |
+6,569
| New | +$1.49M | 0.13% | 176 |
|